ArticlePolymers2025
A Novel Intrauterine Device for the Extended Tissue-Specific Release of Estradiol and Norethindrone to Treat the Genitourinary Syndrome of Menopause.
Article in Polymers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The genitourinary syndrome of menopause (GSM) is a prevalent condition impacting a substantial number of women globally. Presently, the management of GSM typically entails the administration of estrogen via oral, dermal, or vaginal routes for a prolonged period of time. This study involves the development of a polymer-based hollow cylindrical delivery system loaded with estradiol hemihydrate (E2) for prolonged delivery to the uterine cavity (EPHCD) combined with a norethindrone acetate (NETA)-loaded polymeric matrix (NLPM), with both units placed onto an intra-uterine device to form a multi-component drug delivery system for the management of GSM (MCDDS). In developing EPHCD, a central composite design (CCD) was employed to evaluate and optimize the impact of formulation factors on EPHCD release and unit weight loss. The optimized EPHCD was further assessed for its chemical integrity, surface morphology, hydration characteristics, release behavior, ex vivo permeation and cytocompatibility. The optimized EPHCD, which featured a high drug load (10%) and low ethyl cellulose-to-polycaprolactone ratio (EC-to-PCL, 10%), demonstrated favorable attributes with a cumulative drug release and weight loss of 23.78 ± 0.84% and 2.09 ± 0.21%, respectively, over a 4-week testing period. The release kinetics were further noted to obey the Peppas-Sahlin model. Evaluation of MCDDS revealed an in vitro drug release comparable to the individual units, with permeation studies displaying an initial increase in the rate of flux for both drugs during the first 2 h, followed by a subsequent decrease. Moreover, the MCDDS components showed good cytocompatibility against NIH/3T3 cells, with cell viability of more than 70%. Upon evaluation of the MCDDS system, the results of this study highlight its potential as a viable sustained-release intrauterine platform for the treatment of GSM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.